Showing results (321-330 of 352) with videos related to

Sort By:
Pageof 36
Nature Communications|August 16, 2019
Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progressionSilvia Ottaviani, Justin Stebbing, Adam E Frampton, et al.
Journal of the American Geriatrics Society|March 26, 2021
Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A studySergio Salmerón Ríos, Marta Mas Romero, Elisa Belén Cortés Zamora, et al.
Pharmacological Reviews|March 27, 2025
Cell cycle dysregulation in cancerAntonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, et al.
JCO Precision Oncology|December 1, 2021
Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic DiseaseKaren Page, Luke J Martinson, Daniel Fernandez-Garcia, et al.
Journal for Immunotherapy of Cancer|December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic SarcomasBreelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.
Gastroenterology|October 15, 2013
MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progressionAdam E Frampton, Leandro Castellano, Teresa Colombo, et al.
Journal of the American Geriatrics Society|December 11, 2021
Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A StudySergio Salmerón Ríos, Elisa Belén Cortés Zamora, Almudena Avendaño Céspedes, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 29, 2024
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatmentAntonino Glaviano, Seth A Wander, Richard D Baird, et al.
Pageof 36